Ke Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ke Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Weihua Xiao
Shanghai Key Lab of Human Performance, Shanghai University of Sport, Shanghai, China
7 shared publications - Wenhong Wang
School of Physical Education and Health, Zunyi Medical University, Zunyi 563000, China
6 shared publications - Jiabin Wu
Shanghai Key Lab of Human Performance (Shanghai University of sport), Shanghai University of Sport, Shanghai 200438, China; The Key Lab of Exercise and Health Sciences of Ministry of Education, Shanghai University of Sport, Shanghai 200438, China
4 shared publications - Haoyang Gao
Shanghai Key Lab of Human Performance, Shanghai University of Sport, 650 Qingyuan Ring Road, Yangpu District, Shanghai 200438, China
2 shared publications Mingyu Wu
Shanghai Key Lab of Human Performance (Shanghai University of sport), Shanghai University of Sport, Shanghai 200438, China; The Key Lab of Exercise and Health Sciences of Ministry of Education, Shanghai University of Sport, Shanghai 200438, China
2 shared publications- Xiaotong Ma
Shanghai Key Lab of Human Performance, Shanghai University of Sport, Shanghai 200438, China
2 shared publications
Latest Publications
- 27 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 243 (Pt 1) , 117491
Stimulator of interferon genes: A potential target for treating type 2 diabetes mellitus
- 27 October 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 243 (Pt 1) , 117491
Stimulator of interferon genes: A potential target for treating type 2 diabetes mellitus
- Open Access
- 11 July 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (7) , 472
Aerobic Exercise Delays Age-Related Sarcopenia in Mice via Alleviating Imbalance in Mitochondrial Quality Control
Background: Sarcopenia is a syndrome associated with aging, characterized by a progressive decline in skeletal muscle mass and function. Its onset compromises the health and longevity of older adults by increasing susceptibility to falls, fractures, and various comorbid conditions, thereby diminishing quality of life and capacity for independent living. Accumulating evidence indicates that moderate-intensity aerobic exercise is an effective strategy for promoting overall health in older adults and exerts a beneficial effect that mitigates age-related sarcopenia. However, the underlying molecular mechanisms through which exercise confers these protective effects remain incompletely understood. Methods: In this study, we established a naturally aging mouse model to investigate the effects of a 16-week treadmill-based aerobic exercise regimen on skeletal muscle physiology. Results: Results showed that aerobic exercise mitigated age-related declines in muscle mass and function, enhanced markers associated with protein synthesis, reduced oxidative stress, and modulated the expression of genes and proteins implicated in mitochondrial quality control. Notably, a single session of aerobic exercise acutely elevated circulating levels of β-hydroxybutyrate (β-HB) and upregulated the expression of BDH1, HCAR2, and PPARG in the skeletal muscle, suggesting a possible role of β-HB–related signaling in exercise-induced muscle adaptations. However, although these findings support the beneficial effects of aerobic exercise on skeletal muscle aging, further investigation is warranted to elucidate the causal relationships and to characterize the chronic signaling mechanisms involved. Conclusions: This study offers preliminary insights into how aerobic exercise may modulate mitochondrial quality control and β-HB–associated signaling pathways during aging.
- 11 July 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (7) , 472
Open AccessAerobic Exercise Delays Age-Related Sarcopenia in Mice via Alleviating Imbalance in Mitochondrial Quality Control
Background: Sarcopenia is a syndrome associated with aging, characterized by a progressive decline in skeletal muscle mass and function. Its onset compromises the health and longevity of older adults by increasing susceptibility to falls, fractures, and various comorbid conditions, thereby diminishing quality of life and capacity for independent living. Accumulating evidence indicates that moderate-intensity aerobic exercise is an effective strategy for promoting overall health in older adults and exerts a beneficial effect that mitigates age-related sarcopenia. However, the underlying molecular mechanisms through which exercise confers these protective effects remain incompletely understood. Methods: In this study, we established a naturally aging mouse model to investigate the effects of a 16-week treadmill-based aerobic exercise regimen on skeletal muscle physiology. Results: Results showed that aerobic exercise mitigated age-related declines in muscle mass and function, enhanced markers associated with protein synthesis, reduced oxidative stress, and modulated the expression of genes and proteins implicated in mitochondrial quality control. Notably, a single session of aerobic exercise acutely elevated circulating levels of β-hydroxybutyrate (β-HB) and upregulated the expression of BDH1, HCAR2, and PPARG in the skeletal muscle, suggesting a possible role of β-HB–related signaling in exercise-induced muscle adaptations. However, although these findings support the beneficial effects of aerobic exercise on skeletal muscle aging, further investigation is warranted to elucidate the causal relationships and to characterize the chronic signaling mechanisms involved. Conclusions: This study offers preliminary insights into how aerobic exercise may modulate mitochondrial quality control and β-HB–associated signaling pathways during aging.
- Open Access
- 5 January 2025
- Published by Elsevier in Pharmacological Research
- Vol. 212, 107571
Ginsenoside Rg1: A bioactive therapeutic agent for diverse liver diseases
- 5 January 2025
- Published by Elsevier in Pharmacological Research
- Vol. 212, 107571
Open AccessGinsenoside Rg1: A bioactive therapeutic agent for diverse liver diseases
- 20 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116992
Andrographolide: A promising therapeutic agent against organ fibrosis
- 20 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 280, 116992
Andrographolide: A promising therapeutic agent against organ fibrosis
- 1 March 2024
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (2) , 975-989
Pterostilbene: a potential therapeutic agent for fibrotic diseases
Fibrosis is a prevailing pathology in chronic diseases and accounts for 45% of deaths in developed countries. This condition is primarily identified by the transformation of fibroblasts into myofibroblasts and the overproduction of extracellular matrix (ECM) by myofibroblasts. Pterostilbene (PTS) is a natural analogue of resveratrol and is most commonly found in blueberries. Research has shown that PTS exerts a wide range of pharmacological effects, such as antioxidant, anti-inflammatory, and anticancer effects. As a result, PTS has the potential to prevent and cure numerous diseases. Emerging evidence has indicated that PTS can alleviate myocardial fibrosis, renal fibrosis, pulmonary fibrosis, hepatic fibrosis, and colon fibrosis via the inhibition of inflammation, oxidative stress, and fibrogenesis effects in vivo and in vitro, and the potential mechanisms are linked to various pathways, including transforming growth factor-β1 (TGF-β1)/small mother against decapentaplegic proteins (Smads) signalling, the reactive oxygen species (ROS)-driven Pitx2c/mir-15b pathway, nuclear factor kappa B (NF-κB) signalling, Kelch-like epichlorohydrin-associated protein-1 (Keap-1)/NF-E2-related factor-2 (Nrf2) cascade, the NLR family pyridine structure domain 3 (NLRP3) pathway, the Janus kinase-2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, and the Src/STAT3 pathway. In this review, we comprehensively summarize the antifibrotic effects of PTS both in vivo and in vitro and the pharmacological mechanisms, pharmacokinetics, and toxicology of PTS and provide insights into and strategies for exploring promising agents for the treatment of fibrosis. Graphical Abstract
- 1 March 2024
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (2) , 975-989
Pterostilbene: a potential therapeutic agent for fibrotic diseases
Fibrosis is a prevailing pathology in chronic diseases and accounts for 45% of deaths in developed countries. This condition is primarily identified by the transformation of fibroblasts into myofibroblasts and the overproduction of extracellular matrix (ECM) by myofibroblasts. Pterostilbene (PTS) is a natural analogue of resveratrol and is most commonly found in blueberries. Research has shown that PTS exerts a wide range of pharmacological effects, such as antioxidant, anti-inflammatory, and anticancer effects. As a result, PTS has the potential to prevent and cure numerous diseases. Emerging evidence has indicated that PTS can alleviate myocardial fibrosis, renal fibrosis, pulmonary fibrosis, hepatic fibrosis, and colon fibrosis via the inhibition of inflammation, oxidative stress, and fibrogenesis effects in vivo and in vitro, and the potential mechanisms are linked to various pathways, including transforming growth factor-β1 (TGF-β1)/small mother against decapentaplegic proteins (Smads) signalling, the reactive oxygen species (ROS)-driven Pitx2c/mir-15b pathway, nuclear factor kappa B (NF-κB) signalling, Kelch-like epichlorohydrin-associated protein-1 (Keap-1)/NF-E2-related factor-2 (Nrf2) cascade, the NLR family pyridine structure domain 3 (NLRP3) pathway, the Janus kinase-2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, and the Src/STAT3 pathway. In this review, we comprehensively summarize the antifibrotic effects of PTS both in vivo and in vitro and the pharmacological mechanisms, pharmacokinetics, and toxicology of PTS and provide insights into and strategies for exploring promising agents for the treatment of fibrosis. Graphical Abstract
- Open Access
- 15 November 2023
- Published by Elsevier in Journal of Ginseng Research
- Vol. 48 (2) , 129-139
The pharmacological role of Ginsenoside Rg3 in liver diseases: A review on molecular mechanisms
- 15 November 2023
- Published by Elsevier in Journal of Ginseng Research
- Vol. 48 (2) , 129-139
Open AccessThe pharmacological role of Ginsenoside Rg3 in liver diseases: A review on molecular mechanisms
- Open Access
- 20 January 2023
- Published by Elsevier in Pharmacological Research
- Vol. 188, 106657
Astaxanthin: A promising therapeutic agent for organ fibrosis
- 20 January 2023
- Published by Elsevier in Pharmacological Research
- Vol. 188, 106657
Open AccessAstaxanthin: A promising therapeutic agent for organ fibrosis